ReviewRegenerative therapy2026
Concentrated growth factor in oral bone regeneration: A narrative review.
Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Concentrated growth factor (CGF), a third-generation autologous platelet concentrate, has been increasingly used in oral bone regeneration. This review summarizes its preparation, biological mechanisms, and clinical efficacy, and discusses current limitations and future directions. Methods: We comprehensively reviewed the literature on CGF preparation, structural features, and bioactive components, and synthesized clinical evidence across various oral bone defect scenarios. Results: CGF forms a dense three-dimensional fibrin matrix that supports sustained release of growth factors over several days, provides structural support for cell adhesion and proliferation, and modulates the immune microenvironment by promoting macrophage M2 polarization. Through these mechanisms, CGF enhances the coupling of angiogenesis and osteogenesis. Clinically, when used alone or in combination with bone grafts, CGF reduces postoperative complications, accelerates tissue healing, and improves new bone quality in conditions including alveolar ridge preservation, periodontal intraosseous defects, sinus floor elevation, and peri-implant bone defects. Conclusions: CGF is a bioactive autologous material with multi-mechanistic benefits for bone regeneration. However, its clinical translation is constrained by a lack of standardized preparation protocols, inter-individual variability in product quality, and insufficient high-level evidence from large-scale randomized controlled trials. Future research should prioritize protocol standardization and well-designed multicenter trials to establish its definitive role in regenerative dentistry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.